Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

(THE CONVERSATION) Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person’s risk of stroke, heart failure and even premature death. While many risk factors contribute to A ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically ...

On the second Wednesday of the month at 10 a.m., witness a special showcase of local spinners sharing how they craft fibers ...